Contact information
lucinda.griffiths@oncology.ox.ac.uk
octo-trialdev@oncology.ox.ac.uk
+44 (0) 1865617012
She/her
Lucinda (Lucy) Griffiths
BSc Econ (Hons.)
Senior Trial Development Manager
- Oncology Clinical Trial Office (OCTO)
Lucy's experience within clinical trial management spans almost 16 years (13 of those working with CTIMPs), during which she has gained a comprehensive range of experience, skills and in-depth knowledge and understanding of ICH-GCP, trial methodology, clinical research structures and management, applicable regulatory and ethical systems, and the importance of working to these.
Lucy joined the Department of Oncology in June 2011 as a Clinical Trial Administrator in the Oncology Clinical Trial Office (OCTO) before shortly becoming a Trial Manager. In September 2022 Lucy was promoted to work as the Senior Trial Development Manager (STDM) for OCTO, which has since included focussing on clinical trial development for several cancer vaccines and CTIMP based oncology trials, as well as trials with prevention and early detection aims.
The STDM’s role is to work with Chief Investigators and collaborators to oversee all pre-award trial activity associated with the development of new University of Oxford sponsored oncology clinical trial projects, which included protocol development, interfacing with local governance and contract negotiation groups; engagement with local chief investigators; and coordination with academic laboratories and research facilities. The role also includes working closely with the Oxford Cancer team to identify and support opportunities for new trial collaborations.
Before working in OCTO, Lucy worked as a Study Coordinator of over-the-counter medicines and health products clinical trials, for a commercial contract research organisation, which involved running multi-centre studies on-site directly with participants in the UK and in China.
OCTO Trials currently or previously involved with:
LungVax - https://www.oncology.ox.ac.uk/clinical-trials/oncology-clinical-trials-office-octo/prospective-trials/lungvax
EMERALD - Pancreas - Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer
LUD2015-005 - Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer
PEMBLA - Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC)
TARDOX - A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours
6MP - A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours
CHOP-OR -A study of ofatumumab with CHOP chemotherapy for Richter's syndrome (CHOP-OR)
SONATINA - A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer
Recent publications
-
Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors
Conference paper
(2018), Annals of oncology
-
A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies.
Conference paper
Blagden S. et al, (2018), Ann oncol, 29 Suppl 8
-
Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.
Journal article
Lyon PC. et al, (2017), J ther ultrasound, 5
-
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.
Journal article
Eyre TA. et al, (2016), Br j haematol, 175, 43 - 54
-
Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.
Journal article
Hill EJ. et al, (2016), Clin cancer res, 22, 1922 - 1931